Journal profile · Public, Environmental & Occupational Health
Cancer Epidemiology Biomarkers & Prevention
ISSN 1055-9965 · eISSN 1538-7755 · American Association for Cancer Research Inc. · UNITED STATES · Monthly · Founded 1991
Cancer Epidemiology Biomarkers & Prevention: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 3.61; hybrid open access; median 131 days to acceptance (110 articles, last 24 months); community-reported acceptance: about 40%; 864 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Cancer Epidemiology Biomarkers & Prevention is published by American Association for Cancer Research Inc. and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Global Cancer Incidence and Screening, Cancer Risks and Factors and Colorectal Cancer Screening and Detection, together about 33% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Cancer Epidemiology, Biomarkers & Prevention publishes original peer-reviewed, population-based research on cancer etiology, prevention, surveillance, and survivorship. The following topics are of special interest: descriptive, analytical, and molecular epidemiology; biomarkers including assay development, validation, and application; chemoprevention and other types of prevention research in the context of descriptive and observational studies; the role of behavioral factors in cancer etiology and prevention; survivorship studies; risk factors; implementation science and cancer care delivery; and the science of cancer health disparities. Besides welcoming manuscripts that address individual subjects in any of the relevant disciplines, CEBP editors encourage the submission of manuscripts with a transdisciplinary approach.
Source: LetPub
Research area (LetPub): Public, Environmental & Occupational Health
Main research topics OpenAlex counts of recent articles; shares are approximate
- Global Cancer Incidence and ScreeningMedicine16.2%
- Cancer Risks and FactorsMedicine10.2%
- Colorectal Cancer Screening and DetectionMedicine6.7%
- Cervical Cancer and HPV ResearchMedicine6.1%
- Cardiovascular Health and Risk FactorsMedicine5.5%
- BRCA gene mutations in cancerBiochemistry, Genetics and Molecular Biology5.3%
- Nutritional Studies and DietMedicine3.8%
- Nutrition, Genetics, and DiseaseBiochemistry, Genetics and Molecular Biology3.5%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Public, Environmental & Occupational Health | Zone 2 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
| Minor | Public, Environmental & Occupational Health | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
| Minor | Public, Environmental & Occupational Health | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.61LetPub ·
- CiteScore 2026-06
- 5.4LetPub ·
- SJR 2026-06
- 1.43LetPub ·
- SNIP 2026-06
- 1.03LetPub ·
- h-index
- 177LetPub ·
- h-index
- 212OpenAlex ·
- i10-index
- 5,639OpenAlex ·
- 2-year mean citedness
- 0.92OpenAlex ·
- Self-citation rate
- 2.7%LetPub ·
- Share of gold OA articles
- 19.12%LetPub ·
Volume
- Articles per year
- 244LetPub ·
Articles by year OpenAlex count · 13,916 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 196 | 82 | 32 |
| 2025 | 864 | 164 | 491 |
| 2024 | 764 | 151 | 1,151 |
| 2023 | 1,194 | 190 | 2,142 |
| 2022 | 582 | 254 | 3,727 |
| 2021 | 431 | 277 | 6,092 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
131 daysMedian, submission to acceptance · P25–P75 98 days – 166 days
- Acceptance to online
- median 4 days (40 articles)
- Submission to online
- median 134 days
- Sample
- 110 articles with submission and acceptance dates (540 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 1.6 monthsLetPub ·
- Average acceptance (community reports)
- 40%LetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- American Association for Cancer Research Inc.
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Monthly
- Founded
- 1991
- ISSN
- 1055-9965
- Electronic ISSN
- 1538-7755
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Cancer Epidemiology Biomarkers & Prevention
What CAS zone is Cancer Epidemiology Biomarkers & Prevention in?
In the 2025 upgraded edition of the CAS Journal Ranking, Cancer Epidemiology Biomarkers & Prevention is in Zone 2 of Medicine, and in Zone 2 of the minor category Public, Environmental & Occupational Health / Oncology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Cancer Epidemiology Biomarkers & Prevention?
The latest impact factor listed by LetPub is 3.61; CiteScore 5.4, h-index 212.
How long does peer review take at Cancer Epidemiology Biomarkers & Prevention?
Based on the dates recorded on 110 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 131 days (interquartile range 98–166 days); authors report an average review time of about 1.6 months; the community-reported acceptance is “about 40%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Cancer Epidemiology Biomarkers & Prevention?
According to LetPub and DOAJ records, Cancer Epidemiology Biomarkers & Prevention is indexed in SCIE and Scopus.
Is Cancer Epidemiology Biomarkers & Prevention open access, and what is the APC?
Cancer Epidemiology Biomarkers & Prevention is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .